Corticosteroids to Treat Pancreatitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-99
SponsorBeth Israel Deaconess Medical Center
About this trial
This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.
Eligibility criteria
Qualifiers
Adult (≥18 years)
Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.
Admission or planned admission to an intensive care unit
SOFA disease severity score ≥3 (or at least 3 points above a known baseline)
Disqualifiers
Known diagnosis of autoimmune pancreatitis
Existing clinical indication for corticosteroids at a dose >5mg of oral prednisone daily (or equivalent)
Contraindication to receiving corticosteroids
Protected populations (prisoners)
Trial design
Treatments tested in this trial
- Hydrocortisone
- Placebo
Treatment groups
86 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov